



1-800-533-1710

Rapid Hereditary Breast Cancer Test

B RTP

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N029000144
PATIENT ID X100420482	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY CLIENT TESTING
COLLECTED 5/29/2023, 8:00 AM	RECEIVED 5/30/2023, 9:37 AM	REPORTED 6/8/2023, 7:02 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100420482
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321

TEST DESCRIPTION

Evaluation of 11 genes associated with hereditary breast cancer

SPECIMEN

WB Whole Blood

RESULT SUMMARY

Pathogenic Variant Detected

RESULT

Gene (Transcript)	Variant	Zygosity	Classification
BRCA1 (NM_007294.4)	c.68_69del p.Glu23Valfs*17 (p.E23Vfs*17) Chr17(GRCh37):g.41276047_41276048del	Heterozygous	Pathogenic

The following heterozygous PATHOGENIC variant was detected:

BRCA1 (NM_007294.4), chr17(GRCh37):g.41276047_41276048del, c.68_69del, p.Glu23Valfs*17 (p.E23Vfs*17)

No additional reportable variants were detected within all other tested genes. See the Genes Analyzed section for a complete list of genes evaluated by this assay.

INTERPRETATION

BRCA1 c.68_69del (p.E23Vfs*17), PATHOGENIC

The heterozygous c.68_69del (p.E23Vfs*17) frameshift variant in the BRCA1 gene (MIM:113705) is an established pathogenic variant. Variants in the BRCA1 gene have been associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome and autosomal recessive Fanconi anemia (1). This result is supportive of a diagnosis of hereditary breast and ovarian cancer (HBOC) syndrome for this individual. This result is also supportive of carrier status for Fanconi anemia. Clinical correlation is recommended. Individuals with certain cancers and pathogenic or likely pathogenic variants in genes involved in the homologous recombination repair pathway may show sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi) and may be eligible for targeted treatments (2).

This result decreases the likelihood but does not rule out the involvement of the genes evaluated in this panel.

Individuals may have a pathogenic variant in one of the interrogated genes that is not detectable by the methods utilized. Additionally, the clinical phenotype that is observed in this individual and/or family may be due to a pathogenic variant or variants in another gene not targeted by this test.



1-800-533-1710

Rapid Hereditary Breast Cancer Test

B RTP

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N029000144
PATIENT ID X100420482	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY CLIENT TESTING
COLLECTED 5/29/2023, 8:00 AM	RECEIVED 5/30/2023, 9:37 AM	REPORTED 6/8/2023, 7:02 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100420482
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

A genetic consultation may be of benefit.

REFERENCES:

- 1) GeneReviews: BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer (<https://www.ncbi.nlm.nih.gov/books/NBK1247/>) (PMID: 20301425)
- 2) Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244-250. doi:10.1200/JCO.2014.56.2728 (PMID 25366685)

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known pathogenic variants. NGS and/or a polymerase chain reaction (PCR)-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for indels less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. See the Genes Analyzed field for a list of genes tested.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com (TEST ID B RTP) for details regarding genes with regions not routinely covered.

GENES ANALYZED

ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN (including promoter), RAD51C, RAD51D, STK11 and TP53

DISCLAIMER

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at



1-800-533-1710

Rapid Hereditary Breast Cancer Test

B RTP

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N029000144
PATIENT ID X100420482	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY CLIENT TESTING
COLLECTED 5/29/2023, 8:00 AM	RECEIVED 5/30/2023, 9:37 AM	REPORTED 6/8/2023, 7:02 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100420482
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321

risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the Rapid Hereditary Breast Cancer Test in the Special Instructions section of the Test Catalog for the most up to date list of genes included in this test.

Reclassification of Variants Policy

See www.mayocliniclabs.com (TEST ID B RTP) for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

PATIENT NAME TESTRNV, IMPLEMENTATION

23-25967



1-800-533-1710

Rapid Hereditary Breast Cancer Test

B RTP

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N029000144
PATIENT ID X100420482	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY CLIENT TESTING
COLLECTED 5/29/2023, 8:00 AM	RECEIVED 5/30/2023, 9:37 AM	REPORTED 6/8/2023, 7:02 PM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100420482
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321

Wei Shen, Ph.D.

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus
Lab Director : WILLIAM G MORICE MD, PHD CLIA Certificate : 24D0404292

Address : 200 FIRST STREET SW
ROCHESTER MN 55905